TP53 and osteosarcoma: In osteosarcoma in vitro models with compromised p53 function, such as MNNG/HOS cells, with mutated p53, or Saos–2 cells, with null p53, a reduction in cell viability was detected, but the calculated combination index (CI) showed there was no synergistic activity between oridonin and Nutlin–3 [28].